Meet us in San Diego, CA, during ASH 2018!
Poster presentations at ASH:
Sunday, December 2, 2018: 6:00 PM-8:00, PM Hall GH
-
Final Analysis of the Dose Escalation, Expansion and Biomarker Correlations in the Ph I/II Trial BGBC003 with the Selective Oral AXL Inhibitor Bemcentinib (BGB324) in Relapsed/Refractory AML and MDS (BerGenBio study reference: BGBC003)
- Sonja Loges MD, PhD et al
- Session: 613, Acute Myeloid Leukemia: Clinical Studies: Poster II
- Presentation number: 2672
-
Therapeutic Potential of Axl Blockade in BCR-ABL Negative Myeloproliferative Neoplasms (MPN)
- Antonia Beitzen-Heineke, MD et al
- Session: 635, Myeloproliferative Syndromes: Basic Science: Poster II
- Presentation number: 3063
For more information please see here or contact partnering@bergenbio.com
